SMITH & NEPHEW PLC
10 March 2021
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM.
On 9 March 2021, the following awards of US$0.20 ordinary shares (the "Shares") in Smith & Nephew plc (the "Company") vested under the Smith & Nephew Global Share Plan 2010.
1. PARTIAL VESTING ON 9 MARCH 2021 OF 2020 EQUITY INCENTIVE PROGRAMME AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2010:
The awards were granted under the Global Share Plan 2010 on 9 March 2020. One third of the Shares vested on 9 March 2021, a further third will vest on 9 March 2022 and the final third will vest on 9 March 2023. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards. The number of Shares acquired includes the dividend equivalent Shares which participants receive on vested Shares.
The following relates to all individuals included in the below notification:
| Reason for the notification | |
| Initial notification /Amendment | Initial notification |
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| Name | Smith & Nephew plc |
| LEI | 213800ZTMDN8S67S1H61 |
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
| Identification code | ISIN: GB0009223206 |
| Nature of the transaction | Partial vesting of Equity Incentive Programme awards granted on 9 March 2020 under the Smith & Nephew Global Share Plan 2010. |
| Date of Transaction | 2021 - 03 - 09 |
| Place of Transaction | London Stock Exchange (XLON) |
| Name (Position) | Director / PDMR | Price (£) | Volume | Aggregated information | Total Ordinary Share Holding following the transaction * | Total Ordinary Share Holding as a % of the Company's ISC following the transaction * |
| Bradley Cannon (President Sports Medicine & ENT) | PDMR | £13.7794
| 5,572 (of which 2,480 were sold and 3,092 retained) | N/A Single Transaction | 78,458.76313 ordinary shares (including 2,101.64550 in ADS') | 0.00887%
|
| Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | £13.7794
| 3,729 (of which 1,759 were sold and 1,970 retained) | N/A Single Transaction | 41,926.19975 ordinary shares | 0.00474%
|
| Myra Eskes (President APAC Region) | PDMR | £13.7794
| 2,906 (of which 0 were sold and 2,906 retained) | N/A Single Transaction | 11,540.94303 ordinary shares | 0.00130%
|
| Simon Fraser (President Advanced Wound Management) | PDMR | £13.7794
| 3,709 (of which 1,104 were sold and 2,605 retained) | N/A Single Transaction | 4,583.79911 ordinary shares | 0.00052%
|
| Mark Gladwell (President Operations & GBS) | PDMR | £13.7794
| 5,276 (of which 2,489 were sold and 2,787 retained) | N/A Single Transaction | 5,588.44339 ordinary shares | 0.00063%
|
| Melissa Guerdan (Chief Quality & Regulatory Affairs Officer) | PDMR | £13.7794
| 4,600 (of which 1,570 were sold and 3,030 retained) | N/A Single Transaction | 5,581.42336 ordinary shares | 0.00063%
|
| Skip Kiil (President Orthopaedics) | PDMR | £13.7794
| 5,309 (of which 2,031 were sold and 3,278 retained) | N/A Single Transaction | 7,071.53744 ordinary shares | 0.00080%
|
| Elga Lohler (Chief HR Officer) | PDMR | £13.7794
| 4,980 (of which 1,967 were sold and 3,013 retained) | N/A Single Transaction | 101,554.00000 ordinary shares (including 3,105.00000 in ADS') | 0.01148%
|
| Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | £13.7794
| 4,841 (of which 1,650 were sold and 3,191 retained) | N/A Single Transaction | 75,891.23565 ordinary shares (including 5,818.25734 in ADS') | 0.00858%
|
| Vasant Padmanabhan (President Research & Development) | PDMR | £13.7794
| 4,822 (of which 1,637 were sold and 3,185 retained) | N/A Single Transaction | 58,796.00000 ordinary shares | 0.00664%
|
| Susan Swabey (Company Secretary) | PDMR | £13.7794
| 1,673 (of which 790 were sold and 883 retained) | N/A Single Transaction | 48,562.83952 ordinary shares | 0.00549%
|
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
2. PARTIAL VESTING ON 9 MARCH 2021 OF CONDITIONAL SHARE AWARDS MADE UNDER THE GLOBAL SHARE PLAN 2010:
The awards were granted under the Global Share Plan 2010 on 9 March 2020. One third of the shares vested on 9 March 2021, a further third will vest on 9 March 2022 and the final third will vest on 9 March 2023. A number of Shares were sold to cover taxation obligations arising on the vesting of the awards.
The following relates to individuals included in the below notification:
| Reason for the notification | |
| Initial notification /Amendment | Initial notification |
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| Name | Smith & Nephew plc |
| LEI | 213800ZTMDN8S67S1H61 |
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| Description of the financial instrument, type of instrument
| Smith & Nephew plc ordinary shares of USD 0.20 each
|
| Identification code | ISIN: GB0009223206 |
| Nature of the transaction | Partial vesting of a Conditional Share Award granted on 9 March 2020 under the Smith & Nephew Global Share Plan 2010. |
| Date of Transaction | 2021 - 03 - 09 |
| Place of Transaction | London Stock Exchange (XLON) |
| Name (Position) | Director / PDMR | Price (£) | Volume | Aggregated information | Total Ordinary Share Holding following the transaction * | Total Ordinary Share Holding as a % of the Company's ISC following the transaction * |
| Bradley Cannon (President Sports Medicine & ENT) | PDMR | £13.7794
| 6,546 (of which 2,914 were sold and 3,632 retained) | N/A Single Transaction | 82,090.76313 ordinary shares (including 2,101.64550 in ADS') | 0.00928%
|
| Phil Cowdy (Chief Business Development & Corporate Affairs Officer) | PDMR | £13.7794
| 4,603 (of which 2,171 were sold and 2,432 retained) | N/A Single Transaction | 44,358.19975 ordinary shares | 0.00501%
|
| Myra Eskes (President APAC Region) | PDMR | £13.7794
| 6,594 (of which 0 were sold and 6,594 retained) | N/A Single Transaction | 18,134.94303 ordinary shares | 0.00205%
|
| Simon Fraser (President Advanced Wound Management) | PDMR | £13.7794
| 5,608 (of which 1,669 were sold and 3,939 retained) | N/A Single Transaction | 8,522.79911 ordinary shares | 0.00096%
|
| Mark Gladwell (President Operations & GBS) | PDMR | £13.7794
| 6,197 (of which 2,923 were sold and 3,274 retained) | N/A Single Transaction | 8,862.44339 ordinary shares | 0.00100%
|
| Melissa Guerdan (Chief Quality & Regulatory Affairs Officer) | PDMR | £13.7794
| 5,455 (of which 1,862 were sold and 3,593 retained) | N/A Single Transaction | 9,174.42336 ordinary shares | 0.00104%
|
| Skip Kiil (President Orthopaedics) | PDMR | £13.7794
| 8,029 (of which 3,072 were sold and 4,957 retained) | N/A Single Transaction | 12,028.53744 ordinary shares | 0.00136%
|
| Elga Lohler (Chief HR Officer) | PDMR | £13.7794
| 5,849 (of which 2,310 were sold and 3,539 retained) | N/A Single Transaction | 105,093.00000 ordinary shares (including 3,105.00000 in ADS') | 0.01188%
|
| Catheryn O'Rourke (Chief Legal & Compliance Officer) | PDMR | £13.7794
| 5,714 (of which 1,948 were sold and 3,766 retained) | N/A Single Transaction | 79,657.23565 ordinary shares (including 5,818.25734 in ADS') | 0.00900%
|
| Vasant Padmanabhan (President Research & Development) | PDMR | £13.7794
| 5,610 (of which 1,904 were sold and 3,706 retained) | N/A Single Transaction | 62,502.00000 ordinary shares | 0.00706%
|
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
Vickie Reuben
Deputy Company Secretary
Smith & Nephew plc
Tel: +44 (0)1923 477410
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
